BACKGROUND: Surgical and medical androgen deprivation therapy (ADT) strategies are comparable in their ability to suppress serum testosterone levels as treatment in patients with metastatic prostate cancer but differ with regard to cost and impact on quality of life. Medical ADT is associated with better long-term quality of life due to the flexibility of possible therapy interruption but comes with a higher cumulative cost. In the current study, the authors examined whether surgical ADT (ie, bilateral orchiectomy) was used differentially by race/ethnicity and other social factors. METHODS: The authors identified patients with metastatic disease at the time of diagnosis through the California Cancer Registry. The association between race/ethnicity and receipt of surgical ADT was modeled using multivariable Firth logistic regression adjusting for age, Gleason score, prostate-specific antigen level, clinical tumor and lymph node classification, neighborhood socioeconomic status (SES), insurance, marital status, comorbidities, initial treatment (radiotherapy, chemotherapy), location of care, rural/urban area of residence, and year of diagnosis. RESULTS: The authors examined a total of 10,675 patients with metastatic prostate cancer, 11.4% of whom were non-Hispanic black, 8.4% of whom were Asian/Pacific Islander, 18.5% of whom were Hispanic/Latino, and 60.5% of whom were non-Hispanic white. In the multivariable model, patients found to be more likely to receive surgical ADT were Hispanic/Latino (odds ratio [OR], 1.32; 95% confidence interval [95% CI], 1.01-1.72), were from a low neighborhood SES (OR, 1.96; 95% CI, 1.34-2.89) or rural area (OR, 1.49; 95% CI, 1.15-1.92), and had Medicaid/public insurance (OR, 2.21; 95% CI, 1.58-3.10). Patients with military/Veterans Affairs insurance were significantly less likely to receive surgical ADT compared with patients with private insurance (OR, 0.34; 95% CI, 0.13-0.88). CONCLUSIONS: Race/ethnicity, neighborhood SES, and insurance status appear to be significantly associated with receipt of surgical ADT. Future research will need to characterize other differences in initial treatments among men with advanced prostate cancer based on race/ethnicity and aim to better understand what factors drive the association between surgical ADT among men of Hispanic origin or those from areas with low neighborhood SES. Cancer 2019;125:453-462.
INTRODUCTION
Prostate cancer is the most common noncutaneous malignancy diagnosed among men in the United States. 1, 2 Although the majority of men present with localized disease, the incidence of distant metastatic disease at the time of diagnosis has increased. 3 It is well established that prostate cancer affects men differentially based on race/ethnicity, with black men being more likely to present with and die of advanced disease compared with their white counterparts.
Cancer February 1, 2019 Surgical and medical ADT strategies are comparable in their ability to achieve suppressed serum testosterone levels but differ with regard to cost. 12, 13 Although medical ADT, which can be interrupted, is associated with improved quality of life, 14 it also is associated with a greater cost overall and the need for close clinical follow-up for serial drug administration. 15 Alternatively, bilateral orchiectomy is a one-time intervention. 13, 15 Due to differential costs and the need for more regular clinical follow-up in patients receiving medical versus surgical ADT, it is possible that the type of ADT that patients receive is a reflection of disparities in access to consistent treatment as well as physician bias regarding anticipated patient adherence. 16 To the best of our knowledge, there are limited data available regarding the differences in ADT approaches obtained among men with metastatic prostate cancer. The objective of the current study was to use a large population-level data set to more deeply understand the differences in treatments obtained among men with advanced disease. Given the increasing evidence of disparities in receipt of treatment, access to care, and quality of life outcomes among men with prostate cancer, 4, 17, 18 the current study sought to examine whether orchiectomy was used differentially as the primary approach for ADT among men with de novo metastatic prostate cancer by race/ethnicity and other patient social factors, including socioeconomic status (SES), marital status, and health insurance status.
MATERIALS AND METHODS

Data Collection
The current study was an observational cohort study within the population-based California Cancer Registry (CCR), a state-mandated registry that has collected data regarding all cancers diagnosed in residents of California since 1988. The CCR, which comprises 3 regional registries that are members of the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) program, abstracts information regarding patient demographics, tumor characteristics, and initial treatment. Data were obtained regarding all men with de novo metastatic prostate cancer at the time of diagnosis in California from 2004 through 2015, regardless of histologic subtype (13,875 men) . Men diagnosed on death certificate or at the time of autopsy only (21 men) and those who did not receive any form of ADT (3179 men) were excluded from analysis.
The current study was included under the approved institutional review board protocol for the Greater Bay Area cancer registries (SEER San Francisco/Oakland and San Jose/Monterey registries).
Outcome Variable
The primary outcome of this analysis was receipt of bilateral orchiectomy (surgical ADT) as part of initial treatment among men with metastatic prostate cancer at the time of diagnosis.
Demographic Characteristics
The CCR collects race and ethnicity data from medical records and in addition applies an established algorithm 19 based on surname and birthplace to establish Hispanic ethnicity. Patients are categorized by race and ethnicity into the following groups: non-Hispanic (NH) white, NH black, Hispanic, Asian/Pacific Islander, and other/ unknown. Marital status was categorized as married, unmarried, or unknown. Insurance status was categorized as uninsured/unknown, private, Medicaid, Medicare, or military/Veterans Affairs.
The CCR does not collect data regarding individual-level measures of SES. However, because patients' addresses at the time of diagnosis routinely are geocoded by the CCR, we used a previously described composite measure of SES and assigned each case to a quintile of neighborhood SES based on the US Census block group. 20, 21 The Office of Statewide Health Planning and Development (OSHPD) uses population, demographic, and physician data to define Medical Service Study Areas (MSSAs), which are subcounty and subcity geographic areas composed of at least one census tract, and which can be used to characterize health professional shortage areas, medically underserved areas, and medically underserved populations. 22 These MSSAs are characterized as urban, rural, or frontier based on population density. Each patient's residence at the time of diagnosis was classified as being either in an urban or rural/frontier MSSA. In addition, we identified patients who received care at an NCI-designated cancer center.
Clinical Characteristics
We grouped Gleason score into a Gleason score ≤6, a Gleason score of 7, a Gleason score of 8 to 10, or an unknown Gleason score. We described tumor size using clinical T classification categories of ≤T2a, T2b to T2c/ T2NOS, ≥T3a, or Tx. We summarized lymph node status using clinical N classification categories grouped as N0, N1, or Nx. We categorized prostate-specific antigen
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We measured comorbidity burden using the Charlson Comorbidity Index derived from linking CCR data with the OSHPD discharge data. 23 The Charlson Comorbidity Index is a weighted score categorized as 0 (no comorbidity), 1, 2, or ≥3.
The type of ADT received as part of the initial treatment was obtained from the CCR and categorized as no ADT, orchiectomy only, medical ADT only, both orchiectomy and medical ADT, or unknown. Both receipt of radiotherapy and chemotherapy as part of the initial treatment were dichotomized as yes or no.
Statistical Analysis
The use of ADT in men diagnosed with metastatic prostate cancer was characterized. Differences in characteristics between men who received surgical ADT and those who received medical ADT were compared using chisquare tests. The association between race/ethnicity and receipt of surgical ADT was modeled using Firth logistic regression (penalized likelihood method) to reduce small sample bias. 24, 25 Men who received both medical and surgical ADT were included with those who received only surgical ADT; men who had not received ADT (3179 men) were excluded from the current analysis. Covariates considered for inclusion in the multivariable model were age at the time of diagnosis, Gleason score, PSA value at the time of diagnosis, tumor size (T classification), lymph node involvement (N classification), quintile of neighborhood SES, primary health care payer, marital status, Charlson Comorbidity Index, receipt of other primary treatments (radiotherapy, chemotherapy), receipt of care at an NCI-designated cancer center, urban/rural designation of the OSHPD MSSA of the patient's residence at the time of diagnosis, and year of diagnosis. Age at diagnosis and year of diagnosis were included as continuous variables; the remainder were included as categorical variables. A purposeful selection strategy 26 was used to select variables for inclusion in the final multivariable model. All variables that were significant at the P≤.25 level on univariate analysis initially were included in the multivariable model. The model was iteratively reduced, retaining only those variables with a P value <.10. Variables that were not initially included in the model then were added back and retained as significant confounders in the final model if they changed effect estimates by >20%. First-order interactions between race/ethnicity, neighborhood SES, insurance, and rural/ urban status were tested and found not to be significant.
We conducted sensitivity analyses to assess the effect of potential underascertainment of systemic hormone therapy, in which men for whom hormonal therapy was coded as "none," "recommended, unknown if given," or "unknown" (1838 men) were considered as having received hormone therapy.
All analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina). Statistical tests were 2-sided, and values with P <.05 were considered to be statistically significant.
RESULTS
Patient Characteristics
Overall, we identified 10,675 men with metastatic prostate cancer at the time of diagnosis in California from 2004 through 2015. The patient characteristics of the study sample are summarized in Table 1 . Of the men identified, 60.5% were NH white, 11.5% were NH black (black), 18.7% were Hispanic/Latino (Hispanic), and 8.1% were Asian/Pacific Islander (Asian). The majority of the sample were men aged ≥65 years (72.7%), were married (56.1%), and resided in middle or high SES neighborhoods (63.1%). The majority of the sample were insured (94.1%) and nearly one-half of the men were covered by Medicare (47%). The median age of the study sample was 73 years (range, 29-105 years). The majority of the sample had a prostate biopsy performed (58.4%), with a histology type of adenocarcinoma (78.7%), a Gleason score of ≥7 (57.1%), and a PSA level of >20 ng/mL at the time of diagnosis (70.2%). In addition, the majority received initial medical ADT (74.2%), without initial radiotherapy (80.2%) or initial chemotherapy (91.7%). A minority of the sample received care at an NCI-designated cancer center (11.7%) and in a rural/ frontier medical service setting (15.5%). The study sample was relatively equally distributed by year of diagnosis.
The overwhelming majority of patients received medical ADT. However, differences based on the type of ADT received were noted across several demographic characteristics. In Table 2 , the patient characteristics were stratified by type of ADT received (surgery vs medical). Compared with the group receiving medical ADT, there were higher percentages of Hispanic men, men living in lower SES neighborhoods or rural medical service areas, men with Medicare or Medicaid/public insurance, unmarried men, men with disease classified as ≥cT3a, men with unknown lymph node status, and men with PSA levels ≥20 ng/mL in the group of patients who received surgical ADT. The percentage of men with an unknown
Charlson Comorbidity Index was significantly lower in the surgical ADT group. No differences in age at the time of diagnosis were noted by type of ADT received, with the median age being 73 years in both groups. In Figures 1A to 1D , we observed that the percentage of patients who received medical ADT increased over time across all insurance types, race/ethnicity, neighborhood SES, and rural versus urban settings.
Multivariable Analysis
In the overall model presented in Table 3 regarding the outcome of bilateral orchiectomy as the form of ADT received (with those receiving medical ADT as the reference group), being of Hispanic ethnicity, being of older age, having lower neighborhood SES, having Medicaid/ public insurance status, residing in a rural MSSA, and having unknown lymph node status were associated with an increased likelihood of receiving treatment with bilateral orchiectomy. Conversely, having organ-confined disease (<T3), having a PSA value of 10 to 20 ng/mL, having an unknown Gleason score, having military or Veterans Affairs insurance, being of unknown marital status, having an unknown Charlson Comorbidity Index, receipt of care at an NCI-designated cancer center, and having later years of diagnosis were found to be inversely associated with receipt of bilateral orchiectomy. 
DISCUSSION
The current study observed that race/ethnicity, neighborhood SES, and Medicaid/public insurance were significantly associated with use of orchiectomy over medical forms of ADT. These results are consistent with prior research suggesting that the choice of 2 treatments for prostate cancer that have identical efficacy may differ based on social factors such as SES, insurance, and race/ ethnicity.
27-29
The results of the current univariable and multivariable models demonstrated that Hispanic men with de novo metastatic disease were more likely to receive surgical ADT as initial therapy. Although disparities in outcomes among black men with advanced prostate cancer are well established, 18 to the best of our knowledge less is known regarding Hispanic men with this lethal disease. Chinea et al examined a large cohort of men with prostate cancer and observed that, even among Hispanic men, substantial ethnic heterogeneity exists and may influence prostate cancer-specific mortality. 30 Unfortunately, in cancer registry data, >40% of Hispanic/Latino patients have unspecified Hispanic origin. Therefore, future research will need to examine disaggregated race/ethnicity data to determine whether differences in ADT strategy exist among different subgroups (eg, Mexican American, Puerto Rican) and whether cultural factors contribute to observed disparities.
In the current study, we observed that men with Medicaid insurance were more likely to receive surgical ADT as part of their initial treatment. Prior research has demonstrated that patients with cancer who are uninsured or who have Medicaid insurance may have worse outcomes compared with patients with private health insurance. 31, 32 Further research is needed to determine whether the cumulative cost differential between surgical and medical ADT is a driver of differences in the type of ADT received.
We observed that men from lower SES neighborhoods were more likely to undergo surgical ADT. Overall, the results of the current study add to the growing body of literature characterizing the influence of contextual-level SES on outcomes among men with prostate cancer. 33 In prior research, the burden of travel has been shown to affect the receipt of medical care, 34 and specifically cancer care. [35] [36] [37] Because individuals diagnosed in rural settings were more likely to receive surgical ADT, these results support the idea that travel burden may affect cancer treatment plans, even in individuals with advanced disease. These data highlight the need to clarify whether receipt of surgical ADT among patients from lower neighborhood SES areas was driven by patient preference, physician bias, or cost. Because we lacked information regarding patient-level SES factors such as education and income, the contextual level measure of neighborhood SES also may reflect residual confounding by patient SES. In addition, it is possible that the use of surgical ADT is an indicator of physician bias or expectation of patient nonadherence. Therefore, future efforts to better understand the physician perspective in selecting ADT strategies for patients are necessary.
There are a few limitations to the current study that are worth noting. The primary limitation is secondary to the use of cancer registry data in the current study, which may have potential underascertainment of the initial treatment received by patients. Prior research comparing cancer registry data with Medicare claims data demonstrated that cancer registries may underascertain systemic therapy, particularly chemotherapy. 38 However, in a recently completed SEER study that compared CCR treatment data with those from electronic health records, it was found that the sensitivity for capturing hormone therapy in the setting of distant stage prostate cancer was 89%. In the current study, given that approximately 22% of patients did not have ADT noted in the registry, a sensitivity analysis was performed to determine whether the results were different if we assumed patients without documentation of ADT were given medical ADT. This sensitivity analysis did not demonstrate an appreciable difference in results (data not shown). Therefore, this suspected underascertainment is unlikely to affect the conclusions of the current study.
The current study also observed a large number of unknown Charlson Comorbidity indices. These are specifically derived from linkage to OSHPD discharge data. The availability of OSHPD data sources was expanded from inpatient discharge data to also include ambulatory surgery and emergency department discharges starting in 2005. The inverse association we observed with an unknown Charlson Comorbidity Index likely reflects the difference in treatment setting for medical ADT (office/clinic) compared with surgical ADT (ambulatory or inpatient surgery), because an unknown Charlson Comorbidity Index indicates men who had no contact with the California hospital system. In addition, as expected, a higher Charlson Comorbidity Index was not found to be associated with physician use of bilateral orchiectomy, reflecting that this surgical procedure is indeed minor and well tolerated, even within the context of increasing comorbidity.
Despite these limitations, the current study has several strengths. To our knowledge, this is the first contemporary analysis of the type of ADT received by patients in a large population-based sample since lifelong, continuous ADT became the standard of care for patients with metastatic prostate cancer. 11 Most important, we believe the current study adds to the growing literature to characterize the contextual attributes that may contribute to disparities in outcomes among patients with advanced prostate cancer.
